Despite trading below the industry PE ratio, the prospect of negative growth poses some risk. Investors should further research the stock and consider future risks associated with negative growth prospects.
Investor optimism over AerCap Holdings' revenue performance may raise the P/S ratio. However, failing to match growth outlooks could disappoint shareholders. The company may struggle to maintain share prices without short-term industry outperformance.
AerCap's acquisition of GE90 engines from Sanad underscores a strong leasing sector demand. Building relations with major industry players like Sanad could offer AerCap strategic benefits in portfolio growth and future partnerships.
AerCap Holdings' low ROE and high debt usage is of concern, particularly given shifting credit markets. High returns despite significant debt are favourable, but it may backfire if borrowing gets harder.
If you’re going to be forever known for one thing, being the ‘man who broke the Bank of England’ is a description many would sign up for. That is how George Soros is regularly introduced, and the story involves how he bet against the British Pound in 1992 and pocketed $1 billion from the trade in a single day. Of course, Soros’ legendary reputation does not rest solely on that headline-grabbing act, and the billionaire investor has ...
Loop Capital Upgrades$Meta Platforms(META.US)$to Buy, Raises Price Target to $320 Loop Capital analyst Rob Sanderson upgrades Meta Platforms from Hold to Buy and raises the price target from $220 to $320. Loop Capital Downgrades$谷歌-C(GOOG.US)$to Hold, Announces $125 Price Target Loop Capital analyst Rob Sanderson downgrades Alphabet from Buy to Hold and announces $125 price target. $輝盛研究系統(FDS.US)$Receive...
The airline industry is still dealing with issues that have plagued it all year, according to Cowen analyst Helane Becker. These include volatile jet fuel prices, supply chain issues causing delays in maintenance and repair, aircraft delivery delays and difficulty hiring and retaining employees, particularly pilots. We will also be looking for companies to talk about their plans to rein in costs. We are well aware salaries ...
Gainers •$MillerKnoll(MLKN.US)$+12.4%,$BioNTech(BNTX.US)$+7.4%,$Lululemon Athletica(LULU.US)$+6.5% (also authorizes $1 bln stock repurchase program) •$Adagio Therapeutics(ADGI.US)$+52.47% (announces ADG20 (adintrevimab) is the first monoclonal antibody to meet primary endpoints with statistical significance across pre- and post-exposure prophylaxis and treatment for COVID-19 and plans to seek US emergency use authorization) ...
AerCap飛機租賃股票討論區
專欄US Top Gap Ups and Downs on 9/12: ORCL, PKX, CASY, NBIX and More
Gap Ups
1. $Caseys General Stores(CASY.US)$ - up 4.9%
2.$神經分泌生物科學(NBIX.US)$ - up 3.4%
3. $基立福(GRFS.US)$ - up 2.4%
4. $Stellantis NV(STLA.US)$ - up 1.1%
5. $武田製藥(TAK.US)$ - up 1.1%
6. $諾華製藥(NVS.US)$ - up 0.8%
7. $沃達豐(VOD.US)$ - up 0.7%
8. $齊昂銀行(ZION.US)$ - up 0.6...
5年平均淨利爲4.4億,按目前140.9億市值計算,市盈率爲32,估值不便宜。
Billionaire George Soros Loads Up on These 2 ‘Strong Buy’ Stocks
Of course, Soros’ legendary reputation does not rest solely on that headline-grabbing act, and the billionaire investor has ...
專欄US Top Rating Updates on 5/15: META, GOOG, ESS, FDS and More
Loop Capital analyst Rob Sanderson upgrades Meta Platforms from Hold to Buy and raises the price target from $220 to $320.
Loop Capital Downgrades $谷歌-C(GOOG.US)$ to Hold, Announces $125 Price Target
Loop Capital analyst Rob Sanderson downgrades Alphabet from Buy to Hold and announces $125 price target.
$輝盛研究系統(FDS.US)$ Receive...
專欄Airlines Enter Earnings Season Wrestling With Challenges: What to Expect?
We will also be looking for companies to talk about their plans to rein in costs. We are well aware salaries ...
專欄Today's pre-market stock movers: ADGI, LULU, CHWY, MVST and more
• $MillerKnoll(MLKN.US)$ +12.4%, $BioNTech(BNTX.US)$ +7.4%, $Lululemon Athletica(LULU.US)$ +6.5% (also authorizes $1 bln stock repurchase program)
• $Adagio Therapeutics(ADGI.US)$ +52.47% (announces ADG20 (adintrevimab) is the first monoclonal antibody to meet primary endpoints with statistical significance across pre- and post-exposure prophylaxis and treatment for COVID-19 and plans to seek US emergency use authorization)
...
暫無評論